Impact of Subcutaneous Efgartigimod PH20 on Treatment-naïve Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in the ADHERE Trial: Post Hoc Analyses (P1-9.002)
Jeffrey Allen, Hans Katzberg, Kelly Gwathmey, Ken-ichi Kaida, Satoshi Kuwabara, Yessar Hussain, Arne De Roeck, Benjamin Van Hoorick, Geoffrey Istas, Richard Lewis
原始摘要（英文原文）· Original abstract
To assess the efficacy of subcutaneous (SC) efgartigimod PH20 among participants in ADHERE with a time since CIDP diagnosis of <1 year and who had never received CIDP treatment (CIDP treatment-naïve).
Impact of Subcutaneous Efgartigimod PH20 on Treatment-naïve Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in the ADHERE Trial: Post Hoc Analyses (P1-9.002) — 科研速览 Science Skim